Saliva test to predict onset of Alzheimer disease

A Vancouver company, Aurin Biotech, has developed a saliva test that can diagnose Alzheimer disease, as well as predict its future onset, allowing individuals to take preventive measures before the disease takes hold.

The test is based on measuring the concentration of amyloid beta protein 42 (Abeta42) secreted in saliva. Abeta42 is the material that accumulates in the brain of Alzheimer disease cases and causes neuroinflammation, which kills brain neurons. While Abeta42 is made at a constant rate by every organ of the body, it is the brain that decompensates late in life. This allows Abeta42 to precipitate, with consequent development of Alzheimer disease.

The study appears to show that nature tightly controls Abeta42 production in every organ of the body and keeps it at the same production rate throughout life. In normal individuals, this rate is almost exactly the same regardless of sex or age. However, for those destined to develop Alzheimer disease the rate varies, but is two to three times higher.

Researchers acknowledged that the number of cases studied is small, but felt the results were important and should be made widely available, noting that if individuals know they are destined to develop Alzheimer disease, they can initiate preventive measures that may spare them from the disease if commenced well before the age of onset.

The related article, “A method for diagnosing Alzheimer’s disease based on salivary amyloid-ß protein 42 levels,” was published in the Journal of Alzheimers Disease. The article is available online at Aurin Biotech is a private, early-stage Vancouver company developing agents for the treatment of Alzheimer disease and other chronic degenerative diseases.

. Saliva test to predict onset of Alzheimer disease. BCMJ, Vol. 59, No. 1, January, February, 2017, Page(s) 56 - News.

Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.

For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit

BCMJ Guidelines for Authors

Leave a Reply